Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 0.4%

Atea Pharmaceuticals, Inc. (NASDAQ:AVIRGet Rating) dropped 0.4% during trading on Monday . The stock traded as low as $4.61 and last traded at $4.68. Approximately 461,444 shares traded hands during mid-day trading, an increase of 27% from the average daily volume of 364,469 shares. The stock had previously closed at $4.70.

Atea Pharmaceuticals Trading Down 0.4 %

The firm has a market capitalization of $389.79 million, a P/E ratio of 13.37 and a beta of 0.18. The company’s fifty day simple moving average is $4.81 and its 200 day simple moving average is $6.32.

Insiders Place Their Bets

In other Atea Pharmaceuticals news, Director Franklin M. Berger sold 16,166 shares of the company’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $5.16, for a total value of $83,416.56. Following the completion of the transaction, the director now directly owns 778,353 shares in the company, valued at approximately $4,016,301.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Franklin M. Berger sold 25,500 shares of the stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $5.15, for a total value of $131,325.00. Following the completion of the transaction, the director now directly owns 794,519 shares in the company, valued at approximately $4,091,772.85. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Franklin M. Berger sold 16,166 shares of the stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $5.16, for a total transaction of $83,416.56. Following the completion of the transaction, the director now owns 778,353 shares of the company’s stock, valued at $4,016,301.48. The disclosure for this sale can be found here. Company insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Advisor Group Holdings Inc. increased its stake in shares of Atea Pharmaceuticals by 78.8% in the 1st quarter. Advisor Group Holdings Inc. now owns 4,070 shares of the company’s stock worth $28,000 after acquiring an additional 1,794 shares in the last quarter. Denali Advisors LLC bought a new position in shares of Atea Pharmaceuticals in the 3rd quarter worth about $25,000. Royal Bank of Canada increased its stake in shares of Atea Pharmaceuticals by 123.6% in the 3rd quarter. Royal Bank of Canada now owns 4,536 shares of the company’s stock worth $26,000 after acquiring an additional 2,507 shares in the last quarter. Amalgamated Bank purchased a new stake in Atea Pharmaceuticals during the 1st quarter valued at about $58,000. Finally, Ronald Blue Trust Inc. purchased a new stake in Atea Pharmaceuticals during the 2nd quarter valued at about $63,000. 68.92% of the stock is currently owned by institutional investors.

About Atea Pharmaceuticals

(Get Rating)

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19.

Read More

Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.